Recent advances in the development of broad-spectrum antiprotozoal agents

Antonio Moreno-Herrera, Sandra Cortez-Maya, Virgilio Bocanegra-Garcia, Bimal Krishna Banik, Gildardo Rivera

Resultado de la investigación: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

2 Citas (Scopus)

Resumen

Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Enta-moeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are part of a large list of human parasitic diseases. Together, they cause more than 500 million infections per year. These protozoa parasites affect both low-and high-income countries and their pharmacological treatments are limited. Therefore, new and more effective drugs in preclinical development could improve overall therapy for parasitic infections even when their mechanisms of action are unknown. In this review, a number of heterocyclic compounds (diamidine, guanidine, quinoline, benzimidaz-ole, thiazole, diazanaphthalene, and their derivatives) reported as antiprotozoal agents are discussed as options for developing new pharmacological treatments for parasitic diseases.

Idioma originalInglés
Páginas (desde-hasta)583-606
Número de páginas24
PublicaciónCurrent Medicinal Chemistry
Volumen28
N.º3
DOI
EstadoPublicada - 2021

Huella

Profundice en los temas de investigación de 'Recent advances in the development of broad-spectrum antiprotozoal agents'. En conjunto forman una huella única.

Citar esto